Renowned Scientists Join Advanced Cell Technology

Apr 24, 2001, 01:00 ET from Advanced Cell Technology Inc.

    WORCESTER, Mass., April 24 /PRNewswire Interactive News Release/ --
 Advanced Cell Technology Inc. (ACT) announced today that it has recruited,
 Drs. Raymond Page, Tanja Dominko, Teruhiko Wakayama and Tony Perry to its
 scientific team.
     Dr. Page joins ACT from PPL Therapeutics Inc., where he developed and
 perfected technologies for production of human therapeutic proteins in
 transgenic livestock.  He also has expertise in nuclear transfer technology
 in farm and laboratory animal species.  Dr. Page will be directing ACT's cell
 differentiation research program for production of therapeutically active
 cells.
     Dr. Dominko joins ACT from the Oregon Regional Primate Center where she
 conducted pioneering research in non-human primate nuclear transfer.  She has
 worked extensively in mammalian embryology and reproductive cell biology and
 is the Senior Editor of the journal, Cloning.  Dr. Dominko will head a team
 dedicated to develop novel methods for dedifferentiation and
 transdifferentiation of mammalian cells for ACT's cell therapy program.
     Drs. Wakayama and Perry join ACT from The Rockefeller University.  Dr.
 Perry developed a novel and efficient method of transgenesis that he
 demonstrated by co-injecting sperm and transgene DNA into unfertilized eggs.
 Dr. Wakayama has pioneered an embodiment of cloning, becoming the first to
 show that mice could be cloned from the cells of adults.  Dr. Wakayama has
 extended this work to generate successive generations of cloned mice.
 Together, with Dr. Perry, he will establish a mouse embryology laboratory at
 ACT to consolidate and extend their pioneering work on cloning and
 transgenesis.  "ACT provides an unparalleled environment in which
 developments in the mouse -- such as our new method of transgenesis -- can be
 applied experimentally to larger species" said Dr. Perry.
     "ACT already boasts a preeminent scientific staff," mentioned Dr. Jose
 Cibelli, Vice President of Research,  "these includes Dr. Philip Damiani,
 endangered species specialist; Dr. Ping Jiang and Dr. Karen B. Chapman,
 molecular biologists, Dr. Sakthikumar Ambady, primordial germ cells, and Dr.
 Robert Lanza, Vice President of Medical and Scientific Development. ACT now
 possessed unrivalled experience in nuclear transfer, stem cell biology and
 tissue engineering across species, we are assembling the Dream Team," he
 adds.
     "We are excited to welcome the new scientists to the team," added Dr.
 Michael West, CEO of ACT.  "While ACT is actively developing its current
 products, we realize that it's not enough to stand still.  It is essential
 that we think continually of the future.  We believe cloning will
 revolutionize many aspects of medicine and agriculture, and these scientists
 will play a critical role in us making it all happen," he said.
 ACT has established its goals in bringing the benefits of nuclear transfer
 and allied technologies to improve agriculture and medicine.  With its wholly
 owned cattle cloning subsidiary, Cyagra LLC, ACT has more than 160 domestic
 and international patents and patent applications including the most
 extensive mammalian cloning patent ever issued.  ACT has made cloning cattle
 affordable and with today's announcement is set to reduce costs further and
 extend the commercialization of its extensive portfolio to additional
 species.
 
     Michael West
     Advanced Cell Technology
     One Innovation Drive
     Biotech Three
     Worcester, MA  01605
     Tel.: 508-756-1212
     Fax: 508-756-4468
 
                     MAKE YOUR OPINION COUNT -- Click Here
               http://tbutton.prnewswire.com/prn/11690X89291425
 
 

SOURCE Advanced Cell Technology Inc.
    WORCESTER, Mass., April 24 /PRNewswire Interactive News Release/ --
 Advanced Cell Technology Inc. (ACT) announced today that it has recruited,
 Drs. Raymond Page, Tanja Dominko, Teruhiko Wakayama and Tony Perry to its
 scientific team.
     Dr. Page joins ACT from PPL Therapeutics Inc., where he developed and
 perfected technologies for production of human therapeutic proteins in
 transgenic livestock.  He also has expertise in nuclear transfer technology
 in farm and laboratory animal species.  Dr. Page will be directing ACT's cell
 differentiation research program for production of therapeutically active
 cells.
     Dr. Dominko joins ACT from the Oregon Regional Primate Center where she
 conducted pioneering research in non-human primate nuclear transfer.  She has
 worked extensively in mammalian embryology and reproductive cell biology and
 is the Senior Editor of the journal, Cloning.  Dr. Dominko will head a team
 dedicated to develop novel methods for dedifferentiation and
 transdifferentiation of mammalian cells for ACT's cell therapy program.
     Drs. Wakayama and Perry join ACT from The Rockefeller University.  Dr.
 Perry developed a novel and efficient method of transgenesis that he
 demonstrated by co-injecting sperm and transgene DNA into unfertilized eggs.
 Dr. Wakayama has pioneered an embodiment of cloning, becoming the first to
 show that mice could be cloned from the cells of adults.  Dr. Wakayama has
 extended this work to generate successive generations of cloned mice.
 Together, with Dr. Perry, he will establish a mouse embryology laboratory at
 ACT to consolidate and extend their pioneering work on cloning and
 transgenesis.  "ACT provides an unparalleled environment in which
 developments in the mouse -- such as our new method of transgenesis -- can be
 applied experimentally to larger species" said Dr. Perry.
     "ACT already boasts a preeminent scientific staff," mentioned Dr. Jose
 Cibelli, Vice President of Research,  "these includes Dr. Philip Damiani,
 endangered species specialist; Dr. Ping Jiang and Dr. Karen B. Chapman,
 molecular biologists, Dr. Sakthikumar Ambady, primordial germ cells, and Dr.
 Robert Lanza, Vice President of Medical and Scientific Development. ACT now
 possessed unrivalled experience in nuclear transfer, stem cell biology and
 tissue engineering across species, we are assembling the Dream Team," he
 adds.
     "We are excited to welcome the new scientists to the team," added Dr.
 Michael West, CEO of ACT.  "While ACT is actively developing its current
 products, we realize that it's not enough to stand still.  It is essential
 that we think continually of the future.  We believe cloning will
 revolutionize many aspects of medicine and agriculture, and these scientists
 will play a critical role in us making it all happen," he said.
 ACT has established its goals in bringing the benefits of nuclear transfer
 and allied technologies to improve agriculture and medicine.  With its wholly
 owned cattle cloning subsidiary, Cyagra LLC, ACT has more than 160 domestic
 and international patents and patent applications including the most
 extensive mammalian cloning patent ever issued.  ACT has made cloning cattle
 affordable and with today's announcement is set to reduce costs further and
 extend the commercialization of its extensive portfolio to additional
 species.
 
     Michael West
     Advanced Cell Technology
     One Innovation Drive
     Biotech Three
     Worcester, MA  01605
     Tel.: 508-756-1212
     Fax: 508-756-4468
 
                     MAKE YOUR OPINION COUNT -- Click Here
               http://tbutton.prnewswire.com/prn/11690X89291425
 
 SOURCE  Advanced Cell Technology Inc.